Biotech has never had more powerful tools. We can edit genes. We can design molecules in silico. We can simulate protein structures with impressive precision. And yet, thousands of rare diseases still have no approved treatment. According to leaders from Insilico Medicine and GenEditBio, the bottleneck is not ambition or technology. It is talent capacity. […]
- AI
- health
